45 people randomly selected to
take AUSTEDO®
45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study 45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study
45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study 45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study
45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study 45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study
45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study 45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study
45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study 45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study
45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study 45 People Randomly Selected to Take AUSTEDO® vs 45 People Randomly Selected to Take Placebo in the clinical study
45 people randomly selected to
take placebo
  • 90 people with Huntington's disease (HD) chorea were studied for 12 weeks.
  • 45 people were randomly selected to take AUSTEDO® and 45 people were randomly selected to take placebo (inactive tablets).
  • People’s involuntary movements were measured at the beginning and end of the study, with movements also being observed at intervals throughout the 12-week period.

Second goal of the study1,3

To evaluate the effects of AUSTEDO® on:

  • Overall HD symptoms, as reported by
    people and their doctors.
  • Limitations on people’s ability to perform
    daily activities.

Receive Updates

Sign up to have information about AUSTEDO® tablets and HD chorea emailed to you.

You are about to leave this site

You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.

Are you a healthcare professional?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?

References: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information Parsippany, NJ. Teva Neuroscience, Inc. 2. Huntington Study Group. Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord. 1996;11(2):136-142. 3. Data on file. Teva Neuroscience, Inc.